scholarly journals A pre-S gene chip to detect pre-S deletions in hepatitis B virus large surface antigen as a predictive marker for hepatoma risk in chronic hepatitis B virus carriers

2009 ◽  
Vol 16 (1) ◽  
pp. 84 ◽  
Author(s):  
Fan-Ching Shen ◽  
Ih-Jen Su ◽  
Han-Chieh Wu ◽  
Yi-Hsuan Hsieh ◽  
Wei-Jen Yao ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Surface Antigen ◽  
Predictive Marker ◽  
Gene Chip ◽  
S Gene ◽  
Chronic Hepatitis B Virus ◽  
B Virus

scholarly journals Serum immunoconglutinin titers during acute and chronic hepatitis B virus infection

1980 ◽  
Vol 28 (3) ◽  
pp. 842-845
Author(s):  
G M Makhdoomi ◽  
M L Tiku ◽  
K R Beutner ◽  
P L Ogra
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Chronic Hepatitis B Virus ◽  
B Virus ◽  
Acute And Chronic Hepatitis ◽  
Surface Antibody

Sera from 99 chronic hepatitis B surface antigen carriers, 12 individuals with acute type B hepatitis, 26 hepatitis B surface antibody-seropositive subjects, and 50 hepatitis B surface antigen, hepatitis B surface antibody-seronegative subjects were evaluated for the presence of serum imunoconglutinis (IKs). The mean serum IK titers of hepatitis B surface antibody-seropositive and hepatitis B virus-seronegative subjects wre 5.3 and 4.9, respectively. The IK titers of subjects with acute and chronic hepatitis B virus infections were 215.4 and 19.1, respectively. These groups also manifested IK titers greater than or equal to > 16 significantly (P < 0.005) more often than controls did. Among chronic hepatitis B surface antigen carriers, high IK titers were associated with low levels of hepatitis B surface antigen. IK titers of individuals chronically infected with hepatitis B virus and having the rheumatoid factor were similar to those of individuals without the rheumatoid factor. Elevated IK titers represent a physiological autoimmune response and may indicate the presence of immune complexes in acute and chronic hepatitis B virus infection.

scholarly journals Sequence Variability of Hepatitis B Virus (HBV) Surface Antigen Gene (S Gene) Among the Non-responders of Antiviral Therapy

2021 ◽  
Author(s):  
Naveed Alam ◽  
Zubaida Daudzai
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antiviral Therapy ◽  
Chronic Hepatitis B ◽  
Surface Antigen ◽  
Sequence Variability ◽  
Serum Samples ◽  
S Gene ◽  
B Virus

Abstract BackgroundHepatitis B Virus (HBV), has been among the wide spread lethal causative agent of mortality in the population of Pakistan. Prolonged administration of antiviral therapy for chronic hepatitis B may result in the development of hepatitis B viral mutants. ObjectivesTo gain insight into the mechanism involved in the sequence variability of Hepatitis B Virus (HBV) surface antigen gene (S gene) among responders and non-responders to antiviral therapy, baseline characteristics of the patients and sequences within the S region were investigated in pre-treatment serum samples of responders and post-treatment serum samples of non-responders. Data collection and methodologyThe data was collected from 15 individuals with chronic hepatitis B from Khyber Pakhtunkhwa (KPK) province, Pakistan. The antiviral response was independent of viral genotypes, and nonresponse to antiviral therapy was associated with a complex variability of the viral mutants as determined by PCR. ResultsThe sequence analysis of the S gene among responders and non-responders patients of pre and post-treatment with antiviral therapy showed variability in DNA sequence marked as Pakistani isolates make a distinct cluster in the phylogenetic tree. The S gene of HBV isolates from KPK province shows some similarities with isolates of other countries. No significant variations of nucleotides in the S gene of HBV was found among the responders and non-responders receiving antiviral therapy indicating that S gene may not be important with respect to treatment outcome. ConclusionIt illustrates that antigenicity of other various HBV proteins can be targeted in order to design more effective vaccines against the local strains.

scholarly journals Comparison of Three Luminescent Immunoassays for Hepatitis B Virus Surface Antigen Quantification during the Natural History of Chronic Hepatitis B Virus Infection

2014 ◽  
Vol 21 (11) ◽  
pp. 1521-1527 ◽  
Author(s):  
Xiao-Dong Cheng ◽  
Liu-Wei Song ◽  
Lin-Lin Fang ◽  
Lin Yang ◽  
Yong Wu ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Serum Samples ◽  
Virus Surface ◽  
Chronic Hepatitis B Virus ◽  
B Virus

ABSTRACTHepatitis B surface antigen (HBsAg) quantification has garnered attention because of its high predictive value in determining treatment responses. The HBsAg quantification assays, such as Architect and Elecsys, are commercially available, and more assays are in development. We aimed to compare the results of the Architect and Elecsys assays with those of a new assay, WTultra. The WTultra HBsAg assay is a sandwich chemiluminescent microplate enzyme immunoassay and provides an alternative choice which is more cost-effective and potentially applicable in developing or resource-constrained countries and areas. A total of 411 serum samples were collected from patients during various phases of chronic hepatitis B (CHB) infection. The samples were assessed using the three assays, and the results were compared and analyzed. The results for the Architect, Elecsys, and WTultra assays were well correlated according to the overall results for the samples (correlation coefficients,rArchitect versus WTultra= 0.936,rArchitect versus Elecsys= 0.952, andrWTultra versus Elecsys= 0.981) and the various infection phases (rArchitect versus WTultraranging from 0.67 to 0.975,rArchitect versus Elecsysranging from 0.695 to 0.982, andrWTultra versus Elecsysranging from 0.877 to 0.99). Additionally, consistent results were observed according to genotype (genotype B:rArchitect versus WTultra= 0.976,rArchitect versus Elecsys= 0.978, andrWTultra versus Elecsys= 0.979; genotype C:rArchitect versus WTultra= 0.950,rArchitect versus Elecsys= 0.963, andrWTultra versus Elecsys= 0.981) and hepatitis B virus (HBV) DNA levels (rArchitect= 0.540,rWTultra= 0.553, andrElecsys= 0.580). In conclusion, the Elecsys and WTultra assays were well correlated with the Architect assay, irrespective of the CHB infection phase or genotype. All of these assays are reliable for HBsAg quantification.

Sign in / Sign up

Export Citation Format

Share Document